It’s still a coin toss – a 50/50 chance of chronic myeloid leukaemia (CML) patients with deep molecular response on tyrosine kinase inhibitors (TKi) maintaining treatment-free remission if they stop treatment. And while some patients are keen to stop at the earliest possible opportunity, others can be reassured that there is minimal risk with continuing ...
Patients keen to take a chance of treatment-free remission
By Mardi Chapman
26 Oct 2018